- Advertise
- OLE Scientific Interchange Workshops
- About OncLive
- Editorial Board
- CureToday.com
- TargetedOnc.com
- CancerNetwork.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
City of Hope | Strategic Alliance Partners
Latest from City of Hope
PARP Inhibitors Could Help Craft Better Personalized Medicine in Prostate Cancer
April 07, 2021
Article
Tanya Dorff, MD, discusses how the FDA approvals of olaparib and rucaparib have paved the way for additional research with PARP inhibitors in metastatic castration-resistant prostate cancer.
Dr. Dorff on the Importance of Somatic Testing in mCRPC
March 22, 2021
Video
Tanya Dorff, MD, discusses the importance of somatic testing in metastatic castration-resistant prostate cancer.
Checkpoint and PARP Inhibition Remain the Focus of Ongoing Research in TNBC
March 10, 2021
Article
The field of triple-negative breast cancer is pushing to improve treatment by answering questions regarding biomarkers of response, defining the utility of neoadjuvant approaches, and exploring potential combinations with checkpoint inhibitors and PARP inhibitors.
Antibody-Drug Conjugates, TKIs Drive Improved Outcomes in HER2+ Breast Cancer
March 03, 2021
Article
The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease.